Novo Nordisk and Hims Partner on Obesity Drug Sales

Novo Nordisk A/S, the manufacturer of the weight-loss drug Wegovy, is set to partner with Hims & Hers Health, Inc. to sell its obesity treatments on the telehealth platform. This agreement marks the end of a legal dispute between the two companies that escalated into a court battle last month. The two companies are expected to announce the details of their partnership as early as Monday, according to reports citing sources familiar with the matter. The collaboration follows a period of tension regarding the distribution of weight-loss medications. The news, reported via Mexico, indicates a shift toward cooperation in the rapidly growing market for obesity drugs. While the specific terms of the settlement have not been made public, the move is expected to broaden consumer access to Novo Nordisk's pharmaceutical products through digital health channels.